Rhinitis Articles & Analysis: Older
28 news found
Fortunately for many of us, and unfortunately for many others, it means flowers will be in bloom after spring rains and some of us will be suffering with seasonal allergic rhinitis, more commonly referred to as hay fever. It’s all about the coughing, the red eyes, and the sneezing from that point on. ...
This article describes a new method to reduce nasal obstruction in patients with chronic rhinitis when conventional medical therapy has failed. Rhinitis is chronic (CR) when symptoms of nasal obstruction, sneezing, itchy nose, and rhinorrhea persist for more than 3 months each year. ...
The company's portfolio includes six clinical-stage programs: a Phase 2b study to treat patients with acne vulgaris or acne, a Phase 2 trial in hypertension, a Phase 2 study to treat patients with eczema (atopic dermatitis), a Phase 2 study to treat migraines, a Phase 2 study to treat rosacea, and a Phase 1b/2a clinical trial in allergic rhinitis, as well as earlier-stage ...
Sulfites can trigger allergy-like reactions to sensitized people, such as wheezing in those suffering from asthma, allergic rhinitis, and urticaria[3]. Additionally, we can find other hidden allergens in beverages, such as pine nuts in craft beer, almonds in some gins, milk in cream liquors, or wheat in beers and spirits. ...
More than 90% of children in the trial had at least one concurrent atopic medical condition such as allergic rhinitis and atopic dermatitis. The primary endpoint was the annualized rate of severe asthma exacerbations over one year, and the key secondary endpoint was the change from baseline in percentage of predicted pre-bronchodilator FEV1 (FEV1pp) at week 12. ...
Hay fever, also known as allergic rhinitis, occurs when allergens like pollen enter the body and the immune system mistakenly identifies them as a threat. For those with allergic rhinitis, the body then responds to the allergen by releasing chemicals that can cause symptoms. ...
In allergy, a clinical investigation in a pollen challenge chamber demonstrated a significant reduction in the main symptoms of allergic rhinitis with the protective effect setting in rapidly and lasting for 4 hours. ...
In allergy, a clinical investigation in a pollen challenge chamber demonstrated a significant reduction in the main symptoms of allergic rhinitis with the protective effect setting in rapidly and lasting for 4 hours. ...
GALWAY, Ireland–Neurent Medical, a company pioneering innovative treatments for chronic inflammatory sino-nasal diseases, today announced Food and Drug Administration (FDA) clearance of its proprietary NEUROMARK™ Rhinitis Neurolysis Therapy™ (RNT). The clearance gives clinicians access to an in-office treatment designed to create lesions to disrupt the posterior ...
” One of the major goals of the World Sinus Health Awareness Day inaugural education campaign is to delineate common ailments of the nose and sinus such as allergic and non-allergic rhinitis and acute and chronic rhinosinusitis (CRS) from COVID-19-related symptoms by comparing and differentiating the symptoms of each based on data-driven clinical information in patient ...
The hires bring deep medical device industry and ear, nose and throat-specific experience to the company that will support commercial advancement of Neurent’s proprietary NEUROMARK™ technology, an innovative in-office treatment for chronic rhinitis. Key hires include: Declan Daly, Chief Financial Officer – Declan brings a wealth of financial leadership to ...
Aerin Medical Aerin Medical has developed the VivAer and RhinAer platform technologies to treat patients suffering from nasal airway obstruction, and chronic rhinitis, respectively. Two-year results from Aerin Medical’s multi-center, prospective study were recently published in the International Forum of Allergy and Rhinology. ...
Food and Drug Administration (FDA) clearance and U.S. commercialization of its proprietary NEUROMARK™ Rhinitis Neurolysis Therapy™, an innovative in-office treatment for chronic rhinitis. ...
The company's portfolio includes multiple clinical-stage programs: a completed Phase 2 study to treat patients with acne vulgaris or acne, a Phase 1b study to treat patients with pediatric eczema (atopic dermatitis), a Phase 2 study to treat patients with adult eczema (atopic dermatitis), a Phase 2 study for the prevention of episodic migraines, and a Phase 1b/2a clinical trial for the treatment ...
The company's portfolio includes multiple clinical-stage programs: a completed Phase 2 study to treat patients with acne vulgaris or acne, a Phase 1b study to treat patients with pediatric eczema (atopic dermatitis), a Phase 2 study to treat patients with adult eczema (atopic dermatitis), a Phase 2 study for the prevention of episodic migraines, and a Phase 1b/2a clinical trial for the treatment ...
About Oral Mucosal Immunotherapy (OMIT) Respiratory allergies affect at least 60 million people in the United States, resulting in 11.1 million visits to the doctor in 2010. 100 million Europeans suffer from allergic rhinitis and 70 million suffer from asthma. Symptomatic treatment, at a global cost of over $25 billion yearly, keeps symptoms at bay temporarily but does not offer ...
Evolve BioSystems, Inc., a global leader dedicated to improving human health through the gut microbiome, today announced a collaboration with Janssen Research & Development, LLC, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, to conduct a clinical study in children at risk for developing atopic dermatitis. The study will assess the effects of introducing a specific gut ...
” About Oral Mucosal Immunotherapy (OMIT) Respiratory allergies affect at least 60 million people in the United States, resulting in 11.1 million visits to the doctor in 2010. 100 million Europeans suffer from allergic rhinitis and 70 million suffer from asthma. Symptomatic treatment, at a global cost of over $25 billion yearly, keeps symptoms at bay temporarily but does ...
Additionally, many children who suffer from atopic dermatitis in their youth also go on to disproportionally suffer from certain diseases later in life, including 43% of children with severe atopic dermatitis before the age of 8 developing asthma and 45% developing allergic rhinitis according to one recent study.2 “Our goal is to alleviate both the symptoms that are ...
” AOBiome has six ongoing clinical programs in acne, eczema, rosacea, allergic rhinitis, migraine, and hypertension, along with multiple ongoing preclinical programs, including ones addressing pulmonary and gastrointestinal disorders. ...